ONTAK

LOE Approaching

denileukin diftitox

BLAVIALPriority Review
Approved
Feb 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15

Clinical Trials (5)

NCT01251952Phase 1Terminated

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

Started Nov 2010
2 enrolled
Multiple Myeloma
NCT01127451Phase 2Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Started Jun 2010
75 enrolled
Stage IIIC MelanomaStage IV Melanoma
NCT00726037Phase 2Terminated

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

Started Oct 2008
7 enrolled
Metastatic Pancreatic Cancer
NCT00632827Phase 2Terminated

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Started Jul 2008
21 enrolled
Peripheral T-Cell Lymphoma
NCT00460109Phase 2Completed

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

Started Apr 2008
24 enrolled
Lymphoma